Trend Of Outsourcing Trials to China, India Raises New Ethics Questions
This article was originally published in PharmAsia News
Executive Summary
The trend by multinational pharmaceutical companies conducting clinical trials in China, India and other nations with emerging economies may be upsetting accepted ethics of trials. Viral Genetics, a U.S. biotech, came under criticism when it conducted a trial of an AIDS drug in China by giving a control group a placebo instead of antiretrovirals, the accepted trial behavior in the Western World. Chinese authorities investigated after several AIDS patients died during the trial, and concluded "no serious violation of ethical principles." That incident highlights increasing concerns over quality, research ethics and lives of patients in outsourced trials. (Click here for more - may require a subscription
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.